贝瑞基因：预计2025年净利润为-1.7亿元至-2.5亿元

Core Viewpoint - Berry Genomics expects a net profit for the fiscal year 2025 to be negative, projected between -250 million to -170 million yuan [1] Group 1: Financial Performance - The company's operating revenue has declined due to factors such as a decrease in birth rates [1] - Operating cash flow remains stable during the reporting period [1] Group 2: Asset Management - The company has conducted a comprehensive review and impairment testing of various assets based on the principle of prudence, leading to cautious provisions for asset impairments [1] - The impairment provisions have had a certain impact on the net profit for the reporting period [1]